Extraskeletal Manifestations in Axial Spondyloarthritis Are Associated With Worse Clinical Outcomes Despite the Use of Tumor Necrosis Factor Inhibitor Therapy

The GLAS cohort was supported by an unrestricted grant from Pfizer. Pfizer had no role in the design, conduct, interpretation, or publication of this study. R. van der Meer, MD, S. Kruidhof, MD, H. Bootsma, MD, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen; S. Arends, PhD, A. Spoorenberg, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, and Rheumatology, Medical Center Leeuwarden, Leeuwarden; R. Bos, MD, F. Wink, MD, Rheumatology, Medical Center Leeuwarden, Leeuwarden, the Netherlands. SA received research grants from Pfizer. FW has received consulting fees from AbbVie and Janssen. AS received research grants from AbbVie, Pfizer, and Novartis; and consulting fees from AbbVie, Pfizer, MSD, Novartis, and UCB. All other authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. R. van der Meer, University Medical Center Groningen, Rheumatology and Clinical Immunology, 9700 RB Groningen, the Netherlands. Email: r.g.van.der.meer@umcg.nl. Accepted for publication August 3, 2021.

The GLAS cohort was supported by an unrestricted grant from Pfizer. Pfizer had no role in the design, conduct, interpretation, or publication of this study. R. van der Meer, MD, S. Kruidhof, MD, H. Bootsma, MD, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen; S. Arends, PhD, A. Spoorenberg, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, and Rheumatology, Medical Center Leeuwarden, Leeuwarden; R. Bos, MD, F. Wink, MD, Rheumatology, Medical Center Leeuwarden, Leeuwarden, the Netherlands. SA received research grants from Pfizer. FW has received consulting fees from AbbVie and Janssen. AS received research grants from AbbVie, Pfizer, and Novartis; and consulting fees from AbbVie, Pfizer, MSD, Novartis, and UCB. All other authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. R. van der Meer, University Medical Center Groningen, Rheumatology and Clinical Immunology, 9700 RB Groningen, the Netherlands. Email: r.g.van.der.meer@umcg.nl. Accepted for publication August 3, 2021.

The GLAS cohort was supported by an unrestricted grant from Pfizer. Pfizer had no role in the design, conduct, interpretation, or publication of this study. R. van der Meer, MD, S. Kruidhof, MD, H. Bootsma, MD, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen; S. Arends, PhD, A. Spoorenberg, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, and Rheumatology, Medical Center Leeuwarden, Leeuwarden; R. Bos, MD, F. Wink, MD, Rheumatology, Medical Center Leeuwarden, Leeuwarden, the Netherlands. SA received research grants from Pfizer. FW has received consulting fees from AbbVie and Janssen. AS received research grants from AbbVie, Pfizer, and Novartis; and consulting fees from AbbVie, Pfizer, MSD, Novartis, and UCB. All other authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. R. van der Meer, University Medical Center Groningen, Rheumatology and Clinical Immunology, 9700 RB Groningen, the Netherlands. Email: r.g.van.der.meer@umcg.nl. Accepted for publication August 3, 2021.

The GLAS cohort was supported by an unrestricted grant from Pfizer. Pfizer had no role in the design, conduct, interpretation, or publication of this study. R. van der Meer, MD, S. Kruidhof, MD, H. Bootsma, MD, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen; S. Arends, PhD, A. Spoorenberg, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, and Rheumatology, Medical Center Leeuwarden, Leeuwarden; R. Bos, MD, F. Wink, MD, Rheumatology, Medical Center Leeuwarden, Leeuwarden, the Netherlands. SA received research grants from Pfizer. FW has received consulting fees from AbbVie and Janssen. AS received research grants from AbbVie, Pfizer, and Novartis; and consulting fees from AbbVie, Pfizer, MSD, Novartis, and UCB. All other authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. R. van der Meer, University Medical Center Groningen, Rheumatology and Clinical Immunology, 9700 RB Groningen, the Netherlands. Email: r.g.van.der.meer@umcg.nl. Accepted for publication August 3, 2021.

The GLAS cohort was supported by an unrestricted grant from Pfizer. Pfizer had no role in the design, conduct, interpretation, or publication of this study. R. van der Meer, MD, S. Kruidhof, MD, H. Bootsma, MD, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen; S. Arends, PhD, A. Spoorenberg, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, and Rheumatology, Medical Center Leeuwarden, Leeuwarden; R. Bos, MD, F. Wink, MD, Rheumatology, Medical Center Leeuwarden, Leeuwarden, the Netherlands. SA received research grants from Pfizer. FW has received consulting fees from AbbVie and Janssen. AS received research grants from AbbVie, Pfizer, and Novartis; and consulting fees from AbbVie, Pfizer, MSD, Novartis, and UCB. All other authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. R. van der Meer, University Medical Center Groningen, Rheumatology and Clinical Immunology, 9700 RB Groningen, the Netherlands. Email: r.g.van.der.meer@umcg.nl. Accepted for publication August 3, 2021.

The GLAS cohort was supported by an unrestricted grant from Pfizer. Pfizer had no role in the design, conduct, interpretation, or publication of this study. R. van der Meer, MD, S. Kruidhof, MD, H. Bootsma, MD, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen; S. Arends, PhD, A. Spoorenberg, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, and Rheumatology, Medical Center Leeuwarden, Leeuwarden; R. Bos, MD, F. Wink, MD, Rheumatology, Medical Center Leeuwarden, Leeuwarden, the Netherlands. SA received research grants from Pfizer. FW has received consulting fees from AbbVie and Janssen. AS received research grants from AbbVie, Pfizer, and Novartis; and consulting fees from AbbVie, Pfizer, MSD, Novartis, and UCB. All other authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. R. van der Meer, University Medical Center Groningen, Rheumatology and Clinical Immunology, 9700 RB Groningen, the Netherlands. Email: r.g.van.der.meer@umcg.nl. Accepted for publication August 3, 2021.

The GLAS cohort was supported by an unrestricted grant from Pfizer. Pfizer had no role in the design, conduct, interpretation, or publication of this study. R. van der Meer, MD, S. Kruidhof, MD, H. Bootsma, MD, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen; S. Arends, PhD, A. Spoorenberg, PhD, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, and Rheumatology, Medical Center Leeuwarden, Leeuwarden; R. Bos, MD, F. Wink, MD, Rheumatology, Medical Center Leeuwarden, Leeuwarden, the Netherlands. SA received research grants from Pfizer. FW has received consulting fees from AbbVie and Janssen. AS received research grants from AbbVie, Pfizer, and Novartis; and consulting fees from AbbVie, Pfizer, MSD, Novartis, and UCB. All other authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. R. van der Meer, University Medical Center Groningen, Rheumatology and Clinical Immunology, 9700 RB Groningen, the Netherlands. Email: r.g.van.der.meer@umcg.nl. Accepted for publication August 3, 2021.